- Home
- » Tags
- » Pirarubicin
Top View
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- Pirarubicin Reduces USP22 Expression by Inhibiting CREB‑1 Phosphorylation in Hela Cells
- Antineoplastic-Related Cardiovascular Toxicity a Systematic Review And
- United States Patent $835 a 88: As: Inhibitor 1-((R)-3-(4-Amino-3-(4
- Pdf 480.92 K
- Methods for Bladder Cancer Diagnosis – the Role of Autofluorescence And
- Lidocaine Enhances the Effects of Chemotherapeutic Drugs Against
- Biweekly THP-COPBLM (Pirarubicin, Cyclophosphamide, Vincristine
- (12) Patent Application Publication (10) Pub. No.: US 2004/0038904 A1 Ogden (43) Pub
- Effects of Anthracycine Derivatives on Hepatic Neoplastic Nodules of Lewis Lung Carcinoma and Colon Adenocarcinoma 26
- Long‑Term Outcome of 31 Cases of Refractory Acute Promyelocytic
- A Meta-Analysis of Arsenic Trioxide Combined with Transcatheter Arterial Chemoembolization for Treatment of Primary Hepatic Carcinoma
- View a Copy of This Licence, Visit
- Bladder Cancer
- Cytostatics in the Aquatic Environment: Analysis, Occurrence, and Possibilities for Removal
- TOP2A Is Overexpressed and Is a Therapeutic Target for Adrenocortical Carcinoma
- Study Protocol – Version 7 Date:29JUL16 1/144
- Molecular Blueprints for Antitumor Drugs
- Pirarubicin Inhibits Multidrug-Resistant Osteosarcoma Cell Proliferation Through Induction of G2/M Phase Cell Cycle Arrest
- Capsaicin Enhances Anti-Proliferation Efficacy of Pirarubicin Via Activating TRPV1 and Inhibiting PCNA Nuclear Translocation in 5637 Cells
- THP-COPBLM (Pirarubicin, Cyclophosphamide
- Chemotherapy-Related Leiomyopathy: a Suggested Morphological Explanation for the Intestinal Dysmotility Affecting Patients Treated with Anthracyclines
- The Molecular Mechanisms of Human Osteosarcoma Cell Apoptosis
- Improved Detection of Nonmuscle Invasive Urothelial Carcinoma of the Bladder Using Pirarubicin Endoscopy: a Prospective, Single-Center Preliminary Study
- Clonogenicassayversusmttassay
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Single Postoperative Instillation for Non-Muscle Invasive Bladder Cancer: Are There Still Any Indication?
- A Phase II Study of Amrubicin As Palliative Chemotherapy for Previously Treated Malignant Pleural Mesothelioma
- Idarubicin, an Anthracycline, Induces Oxidative DNA Damage in The
- Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral
- Redox-Sensitive and Folate-Receptor-Mediated
- Therapeutic Potential of Arsenic Trioxide with Or Without Interferon-Α
- Concept ID Name Class 1319998 Acebutolol Adrenergics 1154343
- Targeting the Microrna-21/AP1 Axis by 5-Fluorouracil and Pirarubicin in Human Hepatocellular Carcinoma
- Intravesical Administration of Pirarubicin Against Superficial
- Oxidative DNA Damage and Apoptosis
- Phase II Clinical and Pharmacological Study of Pirarubicin in Combination with 5-Fluorouracil and Cyclophosphamide in Metastatic Breast Cancer’
- Statistical Analysis Plan
- Microneedles Drug Delivery Systems for Treatment of Cancer: a Recent Update
- Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: an Up-To-Date Review
- Double-Conditioning Regimens Consisting of Thiotepa, Melphalan and Busulfan with Stem Cell Rescue for the Treatment of Pediatric Solid Tumors
- Cheminformatic and Mechanistic Study of Drug Subcellular Transport/Distribution
- Novel Lipoparticles for the Synergistic Chemo-Photodynamic Therapy of the Cancer Cells
- Apaziquone for Treatment of Patients with Non-Muscle-Invasive Bladder Cancer Following Transurethral Resection of Bladder Tumors NDA 208714